Anatumomab mafenatox

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 447727973

| type = mab

| mab_type = Fab

| source = o

| target = TAG-72

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 1370261-50-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 7E628D4GSQ

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,{{cite web|title=Active Biotech|url=http://activebiotech.com/?oid=117&_locale=1|website=activebiotech.com|access-date=25 May 2016}} which acts as a tumor-targeted superantigen.{{cite book| vauthors = Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M |title=Fusion Protein Technologies for Biopharmaceuticals|chapter=Tumor-Targeted Superantigens|year=2013|pages=365–381|publisher=Wiley |doi=10.1002/9781118354599.ch24|isbn=9781118354599}}

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.{{cite web|title=Drug info|url=http://whqlibdoc.who.int/druginfo/INN_1999_list41.pdf|publisher=World Health Organization|access-date=25 May 2016}}

Development was abandoned in 2005.{{cite web | title = Anatumomab mafenatox | url = http://adisinsight.springer.com/drugs/800013422 | work = AdisInsight | publisher = Springer Nature Switzerland AG}}